Here’s why Gilead broke its dealmaking hiatus and splurged $12 billion on a cancer treatment – Business Insider

Here's why Gilead broke its dealmaking hiatus and splurged $12 billion on a cancer treatment
Business Insider
Cancer cells Promising trial data convinced Gilead that Kite had an edge over competitors. jovan vitanovski/Shutterstock. Gilead Sciences bought cancer-immunotherapy company Kite Pharma for $11.9 billion Monday. The acquisition breaks a years-long …
Wall Street closes little changed as Harvey pummels TexasReuters
Gilead-Kite: A Breakthrough. A $12 Billion Deal. Another Expensive DrugForbes
Gilead Overspends to Quiet Deal ClamorBloomberg
Los Angeles Times –Motley Fool –Xconomy –The Denver Post
all 233 news articles »